Collegium Pharmaceutical, Inc. $COLL Stock Acquired by Profund Advisors LLC

Profund Advisors LLC raised its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 621.1% in the third quarter, Holdings Channel.com reports. The firm owned 65,710 shares of the specialty pharmaceutical company’s stock after buying an additional 56,597 shares during the period. Profund Advisors LLC’s holdings in Collegium Pharmaceutical were worth $1,434,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Vise Technologies Inc. raised its stake in shares of Collegium Pharmaceutical by 154.3% in the third quarter. Vise Technologies Inc. now owns 14,844 shares of the specialty pharmaceutical company’s stock worth $324,000 after purchasing an additional 9,006 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in Collegium Pharmaceutical by 26.4% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 10,300 shares of the specialty pharmaceutical company’s stock worth $225,000 after buying an additional 2,150 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Collegium Pharmaceutical by 15.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,940 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 778 shares in the last quarter. BOKF NA grew its holdings in Collegium Pharmaceutical by 45.2% during the third quarter. BOKF NA now owns 20,757 shares of the specialty pharmaceutical company’s stock worth $453,000 after buying an additional 6,462 shares in the last quarter. Finally, Simplify Asset Management Inc. bought a new stake in Collegium Pharmaceutical during the third quarter worth $2,041,000.

Collegium Pharmaceutical Stock Performance

COLL stock opened at $23.68 on Tuesday. The firm has a market cap of $771.02 million, a PE ratio of 3.33, a P/E/G ratio of 0.72 and a beta of 0.73. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The business has a 50 day moving average of $23.23 and a 200-day moving average of $33.24. Collegium Pharmaceutical, Inc. has a 12-month low of $21.43 and a 12-month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. Collegium Pharmaceutical’s revenue was up 6.3% on a year-over-year basis. During the same period last year, the business posted $1.68 earnings per share. As a group, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 6.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Truist Financial began coverage on Collegium Pharmaceutical in a research report on Wednesday, September 9th. They issued a “buy” rating and a $49.00 price target for the company. Piper Sandler reaffirmed a “neutral” rating and set a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Oppenheimer initiated coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 target price for the company. Leerink Partners began coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price for the company. Finally, Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.71.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.